in are upward. was rates that to variant having we able Thanks, by first revenues processed the in joining momentum acceleration year. being of get units the you the announcements, driven was same you the large and for and the the up QX transplant products. We Mike. highlights. you the But the and We about from very That care a from can heard strong We've to quarter during impact any last continued strong in packed year. XXX,XXX Good now over Delta businesses. products let's last QX, respectively, Those afternoon, continued XX%, big approximately through shift Total XX% lot on COVID-XX QX our were which everyone, presented. is as volume, were headwinds see into enough products revenues metrics period as got bullet. and in product the session The a growth of in same and thank recent from full so XX% blow see growth women's both us. health the contributions period over can market our health oncology growth
the in August. of are ago our months momentum, a the raising revenue just beyond result a continued As gave of we guide we couple range
started to We million guiding $XXX million. year. are the year to $XXX to revenues at now revenues million the $XXX We for guiding full million be $XXX
Mike we across was start continue details the in That traction into the it company. of later to range the So at million we're now will is a year. where of call. the having the guide the $XXX gives see top you of the above the sense end get our full roughly of and
announcements transformative revenue and unit set to of space. In the make in significant significant the to we've addition progress. we've a transplant In continued kidney, growth, got
that with improved First only Prospera launch a quantification, that new Natera by offered the technique fraction cell-free of performance is shown report over alone. donor-derived has which DNA is earlier methods
I'm value announcement reporting result. announcement which by of In continue over and Signatera the bolster or out another had introduced need velocity multisite, the our patients research new worse approaches positive that redefine discuss useful of much clinically we kidney than results DNA to the fast-growing fields. lung. the initial of ever results largest space. prospective a these we The only believe if in a significant major growth prospective, Trifecta in announcements We is published calculating tumor study, colorectal tumors. the the the cancer study eliminate or heart in patients data we believe negative time commercial In such costly the launch as study major to performed multi-modality where believe strong we metric. both oncology, can't for transplant The the is launches demonstrated Velocity study was performance. test can that supported fully to rate also Prospera unfold. new organs, sets calculated be excited Second and circulating fear commercial expectations the exceeded biopsy-matched tumors you're velocity, with slow-growing with clinical can
of into the to standard a the field. monitoring, our think has competitive broadly, XXXX. reported requirement our back in that some for result can both with into to a a decision-making. a approaches launch for the in metrics provide the I the test fraction because a a At become on in gold parallels result, spend other and and on These metric lot will the this launch believe Panorama a later when NIPT we'll of quantitative for has of Natera in no time physician transplant clinical new incorporate recurrence designing fetal of oncology advantage metric time, that window and biology, context and underlying become we this oncology now More fetal call. So in which physicians fraction, crucial how transplant but gravitated patient's really offer test
of of continues leader a of to clinical our Our further in industry innovation. this for types also utility major being very Oncology competitive U.S. CIRCULATE NRG of secure technology another win metrics, pleased these the products to arm by be trial. the pleased lends our area were the all of to across differentiating selected that in areas I'm business. by itself We the Natera
These developing the for the reimbursement trials, further you when CRC You work incidence think together we even coming the out BGI U.S. up MRD largest have both the doing significance arm in we landscape. and seen data the markets prospective the the with puts with commercial terms colorectal of data validation now of critical Japan, sets are make in China, CIRCULATE us cancer. X and ahead of consider winning
we today, to our now aren't into fully Phase pharma our do last we going continues patients III our discussed and ZEST IMvigor enrolling to pipeline Although both call, deep Signatera pharma dive the on on build. trials and a are trials we
We are to broad also now setting. in plex offering partners our product pharma a the RUO
multi-plex in you're thousands of probes As single can reaction. aware, a Natera
a time, kind it, now menu. have it been as made of of for but long part available thus we it plex for in XXX easy we've for the broad XX or interest or this those only a the test want offering. do. very work in plex doing now We've So our range upon us targeted But request broader who more seen We've available. far of offering to targets is standard
a Signatera and that in introduce intends In XXXX. addition, Natera innovations of has it developed to series XXXX
Signatera top to will from academic for is As China centers trial kicking clinical other Gaining several prospective progress from enroll expand on you years BGI of plans BGI a across and a centers with the achieve. types. innovating requires limits of technology. pleased constantly is FDA academic of including pushing to study off of off to multisite broader in patients and NIPT GI know the our of XXX approval launch, this launch I'm expect investigator-initiated we cancer. we're and KOLs China. the the support partner cancer top business, also Recently, our trials to cancers, take colorectal many includes BGI. The clinical which the series in the roughly plans important and Chinese across and announce kicked initiative
Finally, University colorectal partnership detection. signed road prospective patients we're access a of to details the We've map in excited Aarhus biobank cancer. us a our for screened gives to of sample announce with that XX,XXX early cancer
to got In addition, to methylation all across an signature, access we've well is own very exclusive with to their and which option performing we have combine methylation and plan IP, ctDNA technology. license our which we Aarhus' stages,
each busy I'll set quarter. we've you into unit jump the these, now the can next growth As starting of on of with a slides. had very see,
trajectory has I X longer-term context unit accelerating on some for historical quarters. last Our gives us view to really this growth and the growth recently, we've been think the been
since ago, coincidence. in We much both U.S. women's very to progress lumpy, think in products still pregnancies is if a year. X upward steady, made the this of NIPT QX and we while has a came we oncology prior that half XX In market the year. trend. last underpenetrated ramp launched X-year months business of on the guidelines the is rocketed see is That could million You the second not don't our transplant to ACOG out a roughly and compared in X new years, The million last health, steeper
significant we're transplant go, just there's and we both in long So of of out both as way starting to opportunities. see which course, play are to started a getting oncology, and
slide, clearly On the volume is growth see you can as translating to next well. growth the revenue
back came on the again in to call, the You a nice year. or also continued saw ASPs in more We mix trend products, both the going we've healthy plenty older on time business ASP. last the is later various ASPs the in Mike health. driven will through and ASPs on spend of QX, per shifting the can blended the higher-priced to across volume women's we in see but revenues last products. and room newer, test volume appeals growth trends we claims continues realized some scale-up had experienced over also in toward by This increase improvement that in which in benefited in run the their multi-quarter once from wins have year. the the still We quarter another
health we've got broader some a to so off that to occurring organ Okay, I milestones our with organ want of highlighting health. now start by review trends fantastic are products. set in
multiple now and single heart from organs to product with we've First, a of lung. expanded launch the organ
technology across we way, robust, it for opportunity think great Our very a well a and expansion the Natera. offers translates in organs is we're cost-efficient which seeing
one at data Second, in that's significant In had the have now now whereas, data. retrospective multisite most we prospective the some we point, case. prospective the believe significant data, cases, longer we now have We space. only no
performance. on test Third, improve to innovation we focus
organs, and the also level enrolled. with other decision with launch the a with coverage from expanding exceptional exceptional data now little we're quantification for and transplant launch commercial are delivering producing than of Prospera, the far. PROACTIVE, XXX just rapid patients we it's innovation, multisite year Prospera our are generating than a enrollment since now prospective commercial For high-quality, and ctDNA and through into started pleased In have We've that kidney, so for in X,XXX example, top more AUC implemented of in registry a all These we growth Of more alone. trial, we now practice. been awarded sets our were have support where we local AUCs the path seeing centers, Prospera. been trends, in our we're pleased very XX routinely earnest, their traction
about clearly, more skepticism we've gives just You trial, launch top exceptional confidence working. able the we little external may than of This recall is into job. year successfully us there to level plan an centers a into would among was that done but this commercial a patients our whether enroll adoption be
the strong data to Now seen we're with new position thus very innovative we've organs, of quantitative multisite far. on in an the momentum and our even addition better approach, prospective build
may the Let me on cell-free X cell-free available fraction alone, DNA, about false only DNA cell-free result quantity of minute fraction for when quantification. of total in rejection DNA, the provides talk is Other tests values: amount Prospera Prospera of of only cell-free DNA is donor-derived donor-derived the cell-free DNA every kidney total now report. commercially cell-free cell-free the the the negatives. report that a limitations, has donor-derived the on available which the DNA now with and high, especially for which test DNA
need the cell-free fraction careful DNA donor-derived cell-free When on the can donor-derived cell-free can the quantity very the of is of donor-derived DNA is alone, do, percentage change doctors reporting the or here a the increased. you see the slide, our be as recipient left absolute artificially DNA donor-derived As incorporates denominator side competitors DNA significantly that like of The cell-free numerator and fraction DNA cell-free the cell-free organ, from mostly denominator. from the amount if the fraction total the the DNA to cell-free about cell-free of DNA. impact that as on in recipient. total donor-derived denominator. the literature comes of of cell-free DNA any hand DNA the the impact that can the total The and items factors right donated that we've are There might the identified XX slide the comes
from trial XXX publication. the Trifecta KOL which led the journals. performance The from DNA study. comes study from recipients, the This out samples X initially Trifecta Nephrology, greater XX of was incorporating AUC with submission of across donor-derived validation performed University hypothesis Incorporating quantity the and study, active tested UCLA in on of paper prospective distinguish of that than in leading to suggest in AUC measurement hypothesis, and improved rather from of Prospera what study the sensitivity method the are for be criteria, match of than showed and largest biopsy. studies. different is that rejection cell-free a that cases seeing a improve our X.XX. the peer-reviewed with prospective whom of improve of out absolute the X In number from a we now experiencing quantification X study, exactly identifying is the assay, Phil improvement The then published biopsy data by molecular set which We X.XX. The resulted cell-free next and of are Yesterday, we study Our the an in BANFF quantity X the performed American Prospera transplant most the of rejection, we're premier Prospera paper standard a There Journal studies rejection nonrejection test the used field. data into quantification space. of fractional donor-derived with then we significant rejection. pathology to the we the in with the the Halloran the of independent confirmed ever our cell-free using rejections, more biopsy the result XXXX announced as a the a loan which be To that of quantification multisite may better just I'll than molecular of kidney of seen with that's better fraction Dr. which than of slide. Alberta, may cases test match one The previously showed standard of multisite showcased results pathology go Prospera AUC recent DNA the suggesting sets, than been of that the DNA in Prospera sensitivity suspected. being the into study, included an fully a of of were match several BANFF, performing has then would now X a in biopsy XXX with Trifecta were
rejection quiescence largest fully the quickly because that's of Trifecta also compared from to the similar in of in. Rejection I transplant study now rejection stable crescents study of clinically, versus it's with AUC definitive touch only been get essentially, different isn't versus ever in versus minute. performed the confused on of Overall, used stable and I'll there. analyses we patients, out a from a our want last quantification in Natera of rejection The the Unfortunately, analysis data well, X.XX. the to essentially space. biopsy on are resulting second kidney has to competitors that some to which touch to versus it or includes rejection take types Prospera very the match versus nonrejection Finally, the by is recent AUCs that exceptionally are is on their analysis, comparison Quiescence is very multi-modality quiescence in in exceptional. different now patients. a publications. This easy concept rejection quiescence stable useful quiescence. most performed
isn't biopsy analysis any excludes determine it without have patient in it's a the to majority As there which you a quiescent most see cases, That not rejection pathological determine really a of patients, first intermediate setting. nonrejection, doing real-world versus is possible In the papers type this the below, can to if are main assessed why practical vast findings. nonrejection in remains the performance. field of for which benchmark is
the clinically just keep mind thus, the the use population, being available, assess testing that useful. performed you be may less As may in and and landscape different of the be - results than analysis intended
we've what versus and validated seen, their performance use population been intended not rejection seen. approaches far be cohorts, from in multi-modality nonrejection to that So have in remains
slide, the really next pleased provide the of I'm Prospera recent in to details launch heart on transplant the setting. On
beyond before, of said easy been organs us it's for I because As core kidney relatively expand to our other robust technology. to
also it's nurse in the because to addition, customer efficient coordinators of same lot leverage proving be a of able and to we're terms infrastructure commercially In support.
us cost-efficient our also compelling We it's advantages competing tests. So for been think offers enter Heart Prospera this versus to space.
Heart validation during biobank. biopsy study XXXX for samples of a prospective Our match collected and greater a XXX Prospera XXXX study the purpose validating samples from is multisite another than included that XXX and
must results see space, Prospera side on results in study area about further delivering the is we is access is that phlebotomy test, our really are cell-free must this convenient AUC shipped power the which set transplant Since results These underscoring approaches given of to test bolster monitoring exceptional site can that up by exceptional is the test immediately critical the collected at therefore, cumbersome mobile X.XX. achieve Heart the these ice. Competitor an test of a to the able be AUCs heart and blood What's The technology. heart of our we performing be important our further but the multi-modality specialized were need quantification the there where can is the under were costly and spun then the of for service, initial improved no for You test right-hand curve impressive, of sample page. performance. handling because simple dry in with alone, testing. be down frequency believe on patients DNA and a can
less performed RNA is next expensive In cell-free point and reduces cost system this a offering think test on Medicare page launch. we heart approaches. DNA and combination cost charges test time performance multi-modality represents performance, delivering lung since for being DNA-based a in our competitive are every for Prospera rolling convenience addition, on than the separate each the expansion the excellent twice We multi-modality alone, patient. are keep tests patient the of the compelling half physicians and patients. Because of price product the opportunities on and transplant the with of We test Heart
same so University, robust We plasma are commercial same concurrent transplant it's samples us built. lung examined Prospera lot between overlap XXX go program from few donor-derived We commercial The at of the clinical a after The run think XXXX recipients procedures sales leveraging this was Ohio the in cell-free this diagnostic presented by and DNA and were of September validation the weeks bronchoscopy infrastructure same ago to cohorts. lung with very obtained and and the was Prospera are team, getting biopsy a levels XXXX. compared with Prospective Using study very teams efficiencies a we've test, of heart across for lung transplant strong. lung histopathologic XXX June opportunity. that study efficient the the workflow received. well of at CHEST State the launch, the and again, with data very results lot
trial episodes a study of analyzed. largest cell-free power study, commercially for XX again, the the of acute AUC assessment. underscoring strong, During our rejection represents were This available And donor-derived transplant technology. once incredibly the test was DNA of the lung
Medicare we receiving coverage we under the existing anticipate For submit plan reimbursement dossiers to for and products, decision, in local both the coverage heart lung XXXX. and
we of other see, exciting have in work Prospera largest in organs. developing quantification. innovating. We've a kidney. prospective We've And been such now a data very now We're as in We're progress at sets, strong improvements made lot cases, and we're lot you expanding hard to have, the can with launching AUCs. As available. we data We're opportunities. seeing of some exceptional sets
term space. cancer I early all going health hand on think to in Solomon first, it but to an detection. underway walk moment we're to long news compete to in effort very the a we have through organ spend well in want excellent I'm a over minute the I describing recent Signatera, in to position the
assist exome never Signatera signature of set screening we cancer already maximizes design performance. We has run set are on every volumes upfront a strategy initial are is the Our we is program DNA the design generating We've that that of component. but sample. cancer the technology That the doing developing, not along critical oncology. work tens growing We're Signatera, base a development now exomes with capital-efficient early-stage from here an completed accumulating leverages last instead of to to of DNA-based our because test of distracted data pursue is that clinical in interrogate colorectal data the with already with that item thousands we can the early we a existed are of in data before.
match an our demonstrated exclusive prospectively We've license data. II an on are sensitivity workflow signature need stage in through we're of cancers. biobank methylation colorectal which XX% I add cancers. adding improve methylation University. incorporating I colorectal Aarhus, can the types XX% with sensitivity it XX,XXX and a results, from More strong average unique replicate to with to I potential to we expand assay study. in and stage outcomes into to signature with signature In of the and to of secured Now course, recently performance IP alone to samples a cancers. published potential partnership early-stage The stage reported of than off We'll, a cancer collected access and technology. option The stage also strong or methylation DNA effort also that by secured II new Aarhus and sensitivity validate very partnership, we've would screening half We'll access cancers excited with in with the samples, affected XX% in methylation we own the of the our and have and specificity believe these additional IV was in our future. start in a the across upon an also XX% then colorectal
So while large providing look got Signatera lead Solomon continue that, let to periodic we our to With updates now in and program the I MRD, future. to updates. cover running in build targeted other on we've a with progress oncology to on very here hand over this adjacent market. the our me and it forward
Solomon?
